Literature DB >> 27613891

Chronic Nicotine Treatment During Adolescence Attenuates the Effects of Acute Nicotine in Adult Contextual Fear Learning.

Erica D Holliday1, Thomas J Gould2.   

Abstract

INTRODUCTION: Adolescent onset of nicotine abuse is correlated with worse chances at successful abstinence in adulthood. One reason for this may be due to enduring learning deficits resulting from nicotine use during adolescence. Previous work has indicated that chronic nicotine administration beginning in late adolescence (PND38) caused learning deficits in contextual fear when tested in adulthood. The purpose of this study was to determine if chronic nicotine treatment during adolescence would alter sensitivity to nicotine's cognitive enhancing properties in adulthood.
METHODS: C57BL/6J mice received saline or chronic nicotine (12.6mg/kg/day) during adolescence (postnatal day 38) or adulthood (postnatal day 54) for a period of 12 days. Following a 30-day protracted abstinence, mice received either an acute injection of saline or nicotine (0.045, 0.18, and 0.36mg/kg) prior to training and testing a mouse model of contextual fear.
RESULTS: It was found that chronic nicotine administration in adult mice did not alter sensitivity to acute nicotine following a protracted abstinence. In adolescent mice, chronic nicotine administration disrupted adult learning and decreased sensitivity to acute nicotine in adulthood as only the highest dose tested (0.36mg/kg) was able to enhance contextual fear learning.
CONCLUSIONS: These results suggest that adolescent nicotine exposure impairs learning in adulthood, which could increase the risk for continued nicotine use in adulthood by requiring administration of higher doses of nicotine to reverse learning impairments caused by adolescent nicotine exposure. IMPLICATIONS: Results from this study add to the growing body of literature suggesting chronic nicotine exposure during adolescence leads to impaired learning in adulthood and demonstrates that nicotine exposure during adolescence attenuates the cognitive enhancing effects of acute nicotine in adulthood, which suggests altered cholinergic function.
© The Author 2016. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27613891      PMCID: PMC6415932          DOI: 10.1093/ntr/ntw176

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  6 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

2.  Choline ameliorates adult learning deficits and reverses epigenetic modification of chromatin remodeling factors related to adolescent nicotine exposure.

Authors:  Miri Gitik; Erica D Holliday; Ming Leung; Qiaoping Yuan; Sheree F Logue; Roope Tikkanen; David Goldman; Thomas J Gould
Journal:  Neurobiol Learn Mem       Date:  2018-08-09       Impact factor: 2.877

3.  Pre-adolescent and adolescent mice are less sensitive to the effects of acute nicotine on extinction and spontaneous recovery.

Authors:  Munir Gunes Kutlu; Dana Zeid; Jessica M Tumolo; Thomas J Gould
Journal:  Brain Res Bull       Date:  2017-06-15       Impact factor: 4.077

Review 4.  Unique effects of nicotine across the lifespan.

Authors:  Michelle Ren; Shahrdad Lotfipour; Frances Leslie
Journal:  Pharmacol Biochem Behav       Date:  2022-02-03       Impact factor: 3.533

Review 5.  Unique, long-term effects of nicotine on adolescent brain.

Authors:  Frances M Leslie
Journal:  Pharmacol Biochem Behav       Date:  2020-07-30       Impact factor: 3.533

Review 6.  Differential Effects of Nicotine Exposure on the Hippocampus Across Lifespan.

Authors:  Dana Zeid; Munir Gunes Kutlu; Thomas J Gould
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.